Increased expression of the androgen receptor with p300 and interleukin-6 coactivators compensate for oligonucleotide suppression of bcl-2: No increased CREB binding protein or interleukin-4 expression

Therapeutic Advances in Urology

Volumn 5, Issue 2, 2013, Pages 85-93

  Rubenstein, Marvin ^a   Hollowell, Courtney M p ^b   Guinan, Patrick ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Jr Hospital of Cook County   (United States)

Author keywords

androgen receptor; antisense; bcl 2; p300; prostate cancer; therapy

Indexed keywords

ANDROGEN RECEPTOR; CASPASE 3; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; E1A ASSOCIATED P300 PROTEIN; INTERLEUKIN 4; INTERLEUKIN 6; OLIGONUCLEOTIDE; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

EID: 84876363560     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287212466281     Document Type: Article

References (21)

1. American Cancer Society (2012) Cancer Facts & Figures. Atlanta: American Cancer Society.
2. Barton B. (2005) Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes. Expert Opin Ther Targets 9: 737–752.
3. Bouchai J. Santer F. Höschele P. Tomastikova E. Neuwirt H. Culig Z. (2011) Transcriptional coactivators p300 and CBP stimulate estrogen receptor-beta signaling and regulate cellular events in prostate cancer. The Prostate 71: 431–437.
4. Debes J. Comuzzi B. Schmidt L. Dehm S. Culig Z. Tindall D. (2005) P300 regulates androgen receptor-independent expression of prostate specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res 65: 5965–5973.
5. Eder I. Culig Z. Ramoner R. Thurnher M. Putz T. Nessler-Menardi C. (2000) Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Therapy 7: 997–1007.
6. Heemers H. Sebo T. Debes J. Regan K. Raclaw K. Murphy L. (2007) Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res 67: 3422–3430.
7. Huang H. Cheville J. Pan Y. Roche P. Schmidt L. Tindall D. (2001) PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of BCL-2 expression. J Biol Chem 276: 38830–38836.
8. Klocker H. Eder I. Comuzzi B. Bartsch G. Culig Z. (2007) Androgen receptor function in prostate cancer progression. In: Chung L. Isaacs W. Simons J. (eds), Prostate Cancer. New York: Humana Press, p. 94.
9. Jehn C. F. (2006) Cognitive dysfunction, brain-derived neurotrophic factor and IL-6 levels in cancer patients. American Society of Clinical Oncology annual meeting (June 2-6, Atlanta, GA). abstract #8632.
10. Mu Z. Hachem P. Pollack A. (2005) Antisense bcl-2 sensitizes prostate cancer cells to radiation. The Prostate 65: 331–340.
11. Pandini G. Mineo R. Frasca F. Roberts C. Jr. Marcelli M. Vigneri R. (2005) Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res 65: 1849–1857.
12. Rubenstein M. Anderson K. Tsui P. Guinan P. (2006) Synthesis of branched antisense oligonucleotides having multiple specificities: treatment of hormone insensitive prostate cancer. Med Hypoth 67: 1375–1380.
13. Rubenstein M. Dunea G. Guinan P. (1994) Growth factor deprivation therapy utilizing antisense oligonucleotides. Drug News and Perspectives 7: 517–524.
14. Rubenstein M. Guinan P. (2010) Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of Bcl-2 in LNCaP cells. In Vivo 24: 489–493.
15. Rubenstein M. Hollowell C. Guinan P. (2011a) Inhibition of bcl-2 by antisense oligonucleotides is followed by a compensatory suppression of caspase-3 in LNCaP cells. Eur J Clin Med Oncol 3: 1–6.
16. Rubenstein M. Hollowell C. Guinan P. (2011b) In LNCaP cells enhanced expression of the androgen receptor compensates for bcl-2 suppression by antisense oligonucleotides. Ther Adv Urol 3: 73–79.
17. Rubenstein M. Mirochnik Y. Bremer E. George D. Freilich L. Guinan P. (2002) Inhibitory effect of antisense oligonucleotides targeting epidermal growth factor receptor may not be related to changes in mRNA levels in human prostate carcinoma cells. Proceedings AACR 43: 590a.
18. Rubenstein M. Tsui P. Guinan P. (2009) Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors. Comparisons between combination therapies employing bispecific oligonucleotides with either rapamycin or paclitaxel. Med Oncol 26: 124–130.
19. Rubenstein M. Tsui P. Guinan P. (2010) Treatment of prostate and breast tumors employing mono- and bispecific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and Bcl-2. Med Oncol 27: 592–599.
20. Smolen J. Maini R. (2006) Interleukin-6: a new therapeutic target. Arthritis Res Ther 8(Suppl. 2): S5.
21. Yamanaka K. Rocchi P. Miyake H. Fazli L. So A. Zangemeister-wittke U. (2006) Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting bcl-2 and bcl-xL genes. BJU Int 97: 1300–1308.